ArticleBMC geriatrics2025
Exploring the impact of sleep duration and sleep disorders on metabolic dysfunction-associated steatotic liver disease in older adults.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Non-pharmacological treatment of MASLD.Diabetologia · 2026Review
- Article
- Impact of Elovl3 Suppression on Sleep Deprivation-Induced Hepatic Steatosis and Glucose Intolerance in Mice.Cureus · 2026Article
- Revisiting the association between metabolic dysfunction-associated steatotic liver disease and sleep: Moving from correlation to causation.World journal of gastroenterology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThis study investigated the effects of sleep duration and sleep disorders on metabolic dysfunction-associated steatotic liver disease (MASLD) in older adults and provided a scientific basis for the development of targeted health management strategies.
methodsThe present study utilized data from the National Health and Nutrition Examination Survey database of older adults from 2005 to 2014 and included 4,731 participants. The assessment of sleep duration and sleep disorders was conducted using the “Sleep Disorders” questionnaire, while the diagnosis of MASLD was determined based on the fatty liver index and cardiometabolic criteria. The relationship between sleep duration, sleep disorders, and MASLD was analyzed using logistic regression modeling, and the dose-response relationship between sleep duration and MASLD was explored using the restricted cubic spline (RCS) model. Furthermore, subgroup analyses were conducted to investigate the association between sleep disorders and MASLD across diverse population characteristics.
resultsThe study indicated that individuals who slept less than six hours per night exhibited a 21% higher prevalence of MASLD than those who slept six to eight hours. Notably, the prevalence increased substantially, by 38%, in individuals who slept more than eight hours per night. The presence of sleep disorders in individuals was found to be associated with a 2.38-fold elevated prevalence of MASLD compared to those without sleep disorders. Furthermore, the RCS analysis revealed a non-linear relationship between sleep duration and MASLD, indicating an overall “U”-shaped trend with a turning point at 7 h. Subgroup analyses demonstrated that the association remained significant in all subgroups except those with low education levels and stroke patients.
conclusionThe present study found that short or long sleep duration and the presence of sleep disorders were significantly associated with MASLD in older adults. The result provides a rationale for the prevention of MASLD in the elderly population. The study suggests that clinical practice should focus on the potential value of sleep assessment in managing metabolic liver disease. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.